For the treatment of acute stages of COVID-19, clinical studies testing clinically proven NF-κB inhibitors (e.g., aspirin) for their application in COVID-19 therapy might be a highly promising approach, overcoming the limitations of approaches targeting single cytokines [42]. The gene discussed is NFKB1; the disease is COVID-19.